US35661P1003
US35661P1003
Freenome, Inc.
Loading chart...
Company Profile
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
Latest News
Simply Wall St. • 08/11/2026
Freenome (FRNM) Climbed, But What Is Driving Attention Now?
Investor's Business Daily • 07/31/2026
Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 Outlook
GlobeNewswire • 07/27/2026
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
GlobeNewswire • 07/20/2026
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Industry
Website
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
3Y Volatility
27.7% p.a.
Max Drawdown (3Y)
-29.6%
Sharpe Ratio (3Y)
0.69
Beta Factor
0.45
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections